Introduction {#ss1}
============

Amyotrophic lateral sclerosis (ALS) is a refractory and progressive disease that causes selective degeneration of upper and lower motor neurons ([@CIT0001]). Median survival from onset to death in ALS is reported to vary from 20 to 48 months ([@CIT0002]).

Oxidative stress has been considered to be involved in the onset and progression of ALS ([@CIT0003]). An established marker of oxidative stress is 3-nitrotyrosine (3NT), formed by reaction of the free radical peroxynitrite with tyrosine residues. A significant increase of 3NT was reported in spinal cord of transgenic mice expressing mutated SOD1 ([@CIT0004]) and in autopsied spinal cord of FALS patients with genetic mutation of SOD1 and sporadic ALS (SALS) patients ([@CIT0005]). 3NT was found in motor neurons ([@CIT0006],[@CIT0007]) and was elevated in cerebrospinal fluid of SALS patients ([@CIT0008]). Moreover, oxidative stress induces nuclear translocation and activation of Nrf-2, a transcription factor that generates an anti-oxidative response ([@CIT0009]). Nrf-2 translocation also occurs in mutant TDP-43 transfected cultured motor neuron cell lines ([@CIT0010]). Consequently, drugs that eliminate free radicals might protect motor neurons from oxidative stress and free radical damage in ALS patients.

Edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-one, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan) is a free radical scavenger approved for treatment of acute cerebral infarction in Japan in 2001 ([@CIT0013]). Edaravone eliminates lipid peroxides and hydroxyl radicals during cerebral ischemia and protects nerve cells within or around the ischemic region from free radical damage ([@CIT0014]). Beneficial effects of edaravone have been reported in wobbler mice with ALS-like symptoms ([@CIT0017]) and in ALS-model animals ([@CIT0018],[@CIT0019]).

A phase II trial was conducted to investigate the safety and efficacy of edaravone in ALS patients, and found that progression of motor dysfunction was slowed and no clinically significant adverse drug reactions occurred. The level of 3NT was low in cerebrospinal fluid of almost all patients in the phase II trial, suggesting that edaravone could protect neuronal cells from oxidative stress ([@CIT0020]). Therefore we designed a clinical trial to confirm the efficacy and safety of edaravone in ALS patients.

Methods {#ss2}
=======

Standard protocol approvals {#ss3}
---------------------------

Twenty-nine sites in Japan participated in the study between May 2006 and September 2008. An institutional review board at each site approved the study protocol. The study was conducted in compliance with Good Clinical Practice (GCP). All participants provided written informed consent before the pre-observation stage. The study sponsor was Mitsubishi Tanabe Pharma Corporation. The study is registered in ClinicalTrials.gov with a registration number NCT00330681.

Patients {#ss4}
--------

Inclusion criteria were: age 20--75 years; diagnosis of 'definite', 'probable' or 'probable laboratory-supported' ALS ([@CIT0021],[@CIT0022]) according to the revised Airlie House diagnostic criteria; forced vital capacity (FVC) of at least 70%; duration of disease within three years; and change in revised ALS functional rating scale (ALSFRS-R) ([@CIT0023],[@CIT0024]) score during the 12-week pre-observation period of −1 to −4 points. Patients also had a Japanese ALS severity classification ([@CIT0025]) of 1 or 2. (The Japanese ALS severity classification score ranges from 1 to 5 according to the severity classification of the Specified Disease Treatment Research Program for ALS of the Ministry of Health, Labor and Welfare of Japan. Severity Classification: 1) able to work or perform housework; 2) independent living but unable to work; 3) requiring assistance for eating, excretion or ambulation; 4) presence of respiratory insufficiency, difficulty in coughing out sputum or dysphagia; and 5) using a tracheostomy tube, tube feeding or tracheostomy positive pressure ventilation.)

Exclusion criteria were: reduced respiratory function and complaints of dyspnea; complications that may substantially influence evaluation of drug efficacy, such as Parkinson's disease, schizophrenia and dementia; complications that require hospitalization, including liver, cardiac and renal diseases; infections that require antibiotic therapy; deteriorated general condition as judged by investigators; renal dysfunction with creatinine clearance of 50 ml/min or below within 28 days before treatment; and undergoing cancer treatment.

Patient eligibility was assessed with inclusion and exclusion criteria at the start and end of pre-observation.

Administration regimen of riluzole was required not to be changed during the study.

Study medication {#ss5}
----------------

Mitsubishi Tanabe Pharma Corporation provided the investigational drugs in ampoules. Only authorized personnel, independent of the sponsor and investigators, had access to the key code until unblinding. The dose of edaravone was 60 mg per day, which was indicated to show efficacy in the phase II trial ([@CIT0020]), and placebo was chosen since no suitable comparator drug for ALS has been approved. Saline (placebo) or edaravone was administered once daily by i.v. infusion over 60 min.

Design {#ss6}
------

After the 12-week pre-observation period, eligible patients were randomized to placebo or edaravone group. Dynamic allocation was used to minimize the effects of the following three factors, which may substantially influence the evaluation of edaravone:

-   Factor 1: change in ALSFRS-R score during pre-observation period: two categories: −4, −3 or −2, −1.

-   Factor 2: initial symptom: two categories -- bulbar or limb.

-   Factor 3: use of riluzole: two categories -- yes or no.

The study period was 36 weeks, consisting of a 12-week pre-observation period before the start of the first cycle, followed by a 24-week treatment period ([Figure 1](#F1){ref-type="fig"}).

![Trial profile.](AFD-15-610-g001){#F1}

A single treatment cycle consisted of 14 days of study drug administration period followed by a 14-day observation period. Study drugs were administered every day for 14 days in the administration period of the first cycle, and for 10 out of 14 days in the administration periods of cycles 2 to 6. The end of the administration period in each cycle was followed by a 14-day observation period.

Efficacy evaluation {#ss7}
-------------------

Primary efficacy endpoint was the change in ALSFRS-R score. Secondary endpoints were: changes of FVC, grip strength (left/right mean), pinch strength (left/right mean), Modified Norris Scale score ([@CIT0026],[@CIT0027]), ALSAQ-40 (ALS Assessment Questionnaire) ([@CIT0028],[@CIT0029]), and time to death or a specified state of disease progression (incapable of independent ambulation, loss of function in upper limbs, tracheotomy, artificial respirator with intubation, or tube feeding). The evaluations were carried out at the following times: before pre-observation, before the start of the first treatment cycle and at the end of each treatment cycle (after 14 days observation and before the first dosage of the next cycle).

Safety evaluation {#ss8}
-----------------

Safety was assessed in terms of number and severity of adverse events (AE), adverse drug reactions and the results of clinical laboratory tests and sensory tests. Serious adverse events were identified from the adverse events according to the GCP guideline.

Statistical analysis {#ss9}
--------------------

Based upon the experience of the phase II trial ([@CIT0020]), we considered that it would be difficult to enroll more than 100 patients per group for the trial and the target number of patients for enrollment was set at 200. In the phase II trial, the difference of the change of ALSFRS-R between the edaravone and placebo groups was 2.2 for patients with matched severity and dose to those of the present study; and on the assumption of a standard deviation of 5.2, the statistical power of this study can be calculated as 85% when 100 patients per group were enrolled.

The primary population used for the efficacy analysis was the full analysis set (FAS). For ALSFRS-R scores, analysis of covariance (ANCOVA) was performed on the change in score during treatment, defined as the difference between the score before the start of the first treatment cycle (before treatment) and the score at two weeks after the end of the sixth treatment cycle (after treatment). Three factors were used for dynamic allocation as covariates, after which the inter-group difference was assessed. Repeated measures analysis of variance was also performed using the treatment group, period, and interaction between treatment group and period (treatment group × period) as design factors, and baseline value and the three factors used for dynamic allocation as covariates, after which the inter-group difference was assessed. Compound symmetry was assumed as a covariance structure of repeated measurement. Edaravone efficacy would be verified if a significant inter-group difference were found in at least one of the above analyses. A two-sided level of significance of 5% and a two-sided 95% confidence interval were chosen for interpretation of main effect. A two-sided level of significance of 15% was chosen for determining the existence of effect of interaction. A stratified analysis was also performed on the changes of ALSFRS-R score by diagnostic category. The level of significance for differences of patient characteristics was set at 15%.

ANCOVA and repeated measures analysis of variance were similarly performed on the secondary endpoints. Time to death or a specified state of disease progression was defined as an event and the other endpoints were followed until cut-off. A stratified, generalized Wilcoxon test and log-rank test were performed using the change in ALSFRS-R score during the pre-observation period as a stratification factor. For patients with more than one event, the onset date of the first event was defined as the survival time. In censored cases, the cut-off date was the end date of observations.

For patients with missing data at 24 weeks after starting treatment, the last observation carried forward (LOCF) method was applied to impute missing data. Patients who completed the third cycle were eligible for LOCF.

To evaluate safety, AE and adverse drug reactions were assessed in the safety population. Proportions of AE, adverse drug reactions, serious adverse events (SAE) and serious adverse drug reactions were calculated and compared between the groups using Fisher's exact test. A two-sided level of significance of 5% and a two-sided 95% confidence interval were chosen for interpretation. Statistical analysis was performed using SAS software (version 9.1, SAS Institute, Cary, NC).

Results {#ss10}
=======

Subject background {#ss11}
------------------

Two hundred and forty-six patients were prospectively registered. After the 12-week pre-observation period, 40 patients were excluded according to the inclusion and exclusion criteria, and the remaining 206 patients were randomized ([Figure 1](#F1){ref-type="fig"}).

The FAS included 205 patients after exclusion of one patient who was diagnosed with a different disease. For the safety evaluation, the number of patients in the safety population was 206, which included all patients treated with the study medication. The treatment was discontinued for 23 patients (edaravone group: patients' request 5, AE 3, tracheotomy 1; placebo group: patients' request 5, AE 6, tracheotomy 2, protocol violation 1). There was no imbalance between the groups in either analysis set on discontinuation (FAS: *p* = 0.378; safety population: *p* = 0.377).

All patients in the safety population received at least 80% of the assigned dosages of study drug.

Patient characteristics are summarized in [Table I](#T1){ref-type="table"}. Among the patient characteristics, those for which inter-group differences were found at a significance level below 15% were the duration of disease (*p* = 0.104, paired *t*-test), ALSFRS-R score before pre-observation (*p* = 0.065, paired *t*-test), and ALSFRS-R score at the start of the first cycle (*p* = 0.146, paired *t*-test).

###### 

Subject demographic characteristics.

  -------------------------------------------------------------------------------------
  Item                                              Placebo (104)\   Edaravone (101)\
                                                    *n* (%)          *n* (%)
  ------------------------------------------------- ---------------- ------------------
  Gender                                                             

   male                                             69 (66.3)        63 (62.4)

  Initial symptom                                                    

   bulbar                                           20 (19.2)        18 (17.8)

   limb                                             84 (80.8)        83 (82.2)

  Diagnosis (El Escorial revisited)                                  

   definite                                         21 (20.2)        29 (28.7)

   probable                                         54 (51.9)        52 (51.5)

   probable laboratory-supported                    28 (26.9)        20 (19.8)

   possible                                         1 (1.0)          0 (0.0)

  The Japanese severity classification                               

   grade 1                                          40 (38.5)        36 (35.6)

   grade 2                                          64 (61.5)        65 (64.4)

  Use of riluzole                                                    

   yes                                              92 (88.5)        90 (89.1)

  Change in ALSFRS-R score during pre-observation                    

   −4, −3                                           32 (30.8)        29 (28.7)

   −2, −1                                           72 (69.2)        72 (71.3)
  -------------------------------------------------------------------------------------

  ------------------------------------------------------------------------------
  Item                                     Placebo (104)\     Edaravone (101)\
                                           median (min-max)   median (min-max)
  ---------------------------------------- ------------------ ------------------
  Age (years old)                          58.5 (28--75)      58.0 (29--73)

  Body weight (kg)                         57.0 (37--109)     57.0 (35--77)

  Duration of disease (years)              1.20 (0.3--3.0)    1.30 (0.4--2.9)

  ALSFRS-R score before pre-observation    44.0 (35--48)      43.0 (31--48)

  ALSFRS-R score before treatment period   42.0 (32--47)      41.0 (29--47)
  ------------------------------------------------------------------------------

ALSFRS-R: the revised amyotrophic lateral sclerosis functional rating scale.

Efficacy {#ss12}
--------

The results of ANCOVA for the change of ALSFRS-R score during treatment and the results of repeated measures analysis of variance are shown in [Table II](#T2){ref-type="table"}. In both analyses, no significant inter-group difference was observed.

###### 

Change in endpoints during treatment.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          Change in endpoints during treatment (ANCOVA)   Repeated-measures analysis                                                                             
  ----------------------- ----------------------------------------------- ---------------------------- ----------------- ------- -------------- -------------- ----------------- -------
  Primary endpoint                                                                                                                                                               

  ALSFRS-R                −6.35 ± 0.84\                                   −5.70 ± 0.85\                0.65 ± 0.78\      0.411   37.43 ± 0.46   38.08 ± 0.47   0.65 ± 0.44\      0.141
                          (99)                                            (100)                        (−0.90 -- 2.19)                                         (−0.22 -- 1.52)   

  Secondary endpoint                                                                                                                                                             

  %FVC                    −17.49 ± 2.39\                                  −14.57 ± 2.41\               2.92 ± 2.24\      0.193   87.30 ± 1.56   88.56 ± 1.59   1.26 ± 1.46\      0.390
                          (99)                                            (100)                        (−1.49, 7.33)                                           (−1.63, 4.15)     

  Grip strength           −5.71 ± 0.69\                                   −4.81 ± 0.69\                0.89 ± 0.64\      0.165   13.22 ± 0.42   13.83 ± 0.43   0.60 ± 0.40\      0.130
                          (99)                                            (100)                        (−0.37, 2.16)                                           (−0.18, 1.38)     

  Pinch strength          −1.03 ± 0.15\                                   −0.83 ± 0.15\                0.20 ± 0.14\      0.165   2.62 ± 0.11    2.83 ± 0.11    0.21 ± 0.10\      0.038
                          (99)                                            (100)                        −0.08, 0.48)                                            (0.01, 0.41)      

  Modified Norris scale   −16.15 ± 2.00\                                  −14.12 ± 2.05\               2.03 ± 1.89\      0.284   NA             NA             NA                NA
                          (97)                                            (95)                         (−1.69, 5.75)                                                             

  ALSAQ40                 19.13 ± 3.79\                                   19.60 ± 3.82\                0.48 ± 3.50\      0.892   NA             NA             NA                NA
                          (95)                                            (95)                         (−6.44, 7.39)                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALSFRS-R: interaction between treatment group and period (*p* = 0.915). ALSFRS-R: the revised amyotrophic lateral sclerosis functional rating scale. NA: not applicable. For Modified Norris scale and ALSAQ40, repeated measures analysis was not conducted

The changes in ALSFRS-R score during treatment according to diagnostic category, i.e. 'definite', 'probable' and 'probable laboratory-supported', are shown in [Figure 2](#F2){ref-type="fig"}.

![Change of ALSFRS-R score during treatment by diagnostic category. ALSFRS-R: the revised amyotrophic lateral sclerosis functional rating scale.](AFD-15-610-g002){#F2}

The results of secondary endpoints are presented in [Table II](#T2){ref-type="table"}. The pinch strength analyzed by repeated measures analysis of variance showed a statistically significant difference, as there was no interaction between the treatment group and period (*p* = 0.292). The other endpoints did not show a significant difference.

The proportion of events of death or a particular state of disease progression was documented in 27 patients in the placebo group (14 patients with −4, −3 change in ALSFRS-R score during pre-observation, and 13 patients with −2, −1 change) and 32 in the edaravone group (12 patients with −4, −3 change and 20 patients with −2, −1 change). There was no significant inter-group difference (stratified log-rank test: *p* = 0.381, stratified generalized Wilcoxon test: *p* = 0.399).

Safety {#ss13}
------

The proportion of AE reported in the safety population was 88.5% in the placebo group and 89.2% in the edaravone group. All AE and SAE with a proportion of at least 5% in either group are listed ([Table III](#T3){ref-type="table"}). The inter-group difference in proportion with 95% confidence interval is 0.8% (−7.8% to 9.4%). There were no significant inter-group differences in the proportion of AE (*p* = 1.000), and in adverse drug reactions (*p* = 0.349). The proportion of SAE was 23.1% in the placebo group and 17.6% in the edaravone group. Two cases of respiratory failure in the placebo group resulted in death; in the edaravone group, there were three deaths (two cases of respiratory disorder and one case of respiratory failure). The investigators determined that the deaths were due to the primary disease and were not related to the study drug. There was no significant inter-group difference in the proportion of SAE (*p* = 0.389). No serious adverse drug reactions occurred in either group.

###### 

Adverse events and serious adverse events.

                          AE   SAE                                       
  ----------------------- ---- -------- ---- -------- ---- -------- ---- --------
  Total                   92   (88.5)   91   (89.2)   24   (23.1)   18   (17.6)
  Constipation            17   (16.3)   13   (12.7)                      
  Dysphagia               12   (11.5)   8    (7.8)    11   (10.6)   8    (7.8)
  Nasopharyngitis         22   (21.2)   22   (21.6)                      
  Muscular weakness       9    (8.7)    7    (6.9)    1    (1.0)    1    (1.0)
  Contusion               5    (4.8)    12   (11.8)                      
  Headache                3    (2.9)    8    (7.8)                       
  Insomnia                10   (9.6)    9    (8.8)                       
  Gait disturbance        16   (15.4)   20   (19.6)   2    (1.9)    3    (2.9)
  Eczema                  2    (1.9)    7    (6.9)                       
  Glucose urine present   3    (2.9)    6    (5.9)                       

All AE with an incidence greater than 5% are tabulated by the primary term, MedDRA version 11.1.

Discussion {#ss14}
==========

The results of prior clinical trials ([@CIT0020],[@CIT0030]) indicated that edaravone may delay the progression of symptoms in some ALS patients. Because evaluation of edaravone would be difficult in patients in whom ALS progression was either acute or non-existent, only patients whose ALSFRS-R score changed by −1 to −4 points during the 12-week pre-observation period were eligible for the study. Since efficacy was found over the 24-week treatment period in the phase II trial, a treatment period of 24 weeks was also chosen for this study.

Based on the results of the previous phase II trial, the inter-group difference in the change of ALSFRS-R score at the end of treatment was expected to be 2 points in this trial. However, the actual inter-group difference was only 0.65 points by ANCOVA and this was not statistically significant. No significant inter-group difference was found by repeated measures analysis of variance either. The results of ANCOVA for pinch strength, a secondary endpoint, suggested a beneficial effect in the edaravone group compared to the placebo group.

Additionally, stratified analysis by diagnostic category ([Figure 2](#F2){ref-type="fig"}) revealed that the change in ALSFRS-R score during treatment was greater in those patients fulfilling the criteria for clinically definite ALS using the Airlie House diagnostic classification. This trial enrolled patients with longer duration of disease and higher ALSFRS-R scores at the start of treatment compared to those of the patients in other trials ([@CIT0031]). As shown in [Table I](#T1){ref-type="table"}, the mean duration of disease for the edaravone group and the placebo group was 1.3 years and 1.2 years, respectively, and the mean ALSFRS-R score at the start of treatment was 41 and 42, respectively. While the mean change in ALSFRS-R score during the treatment was −5.70 for the edaravone group and −6.35 for the placebo group, our internal analysis showed that 25% of patients in the edaravone group and 26% of patients in the placebo group showed the change of 0 or −1 point in ALSFRS-R score indicating a more slowly progressive form of the disease than had originally been anticipated when the trial was designed, and thus attenuating the power of the study. Future trials will aim to enroll patients with more rapidly progressive illness. AE occurred in nearly 90% of both groups, i.e. 88.5% of patients in the placebo group and 89.2% in the edaravone group, with no significant differences between the two groups.

In conclusion, although the elimination of free radicals to inhibit the degeneration of motor neurons appears to be a promising new strategy for the treatment of ALS, this study failed to demonstrate efficacy of edaravone to delay the progression of ALS. While the primary endpoint was not achieved, we consider that the results are helpful to identify the patient population in which edaravone could be expected to show efficacy. On the basis of this information, we have designed and are conducting a phase III study.
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The Edaravone ALS Study Group: Site Investigators {#ss15}
=================================================
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